Needed to screen multiple gene loci modification strategies in T cells and NK cells to enhance CAR-T cell anti-tumor activity and persistence
Using RNP electroporation method, successfully knocked out checkpoint genes including PD-1 and CTLA-4 in various immune cells such as T cells and NK cells
Identified 2 key gene modifications that increased CAR-T cell persistence by 3-fold and anti-tumor efficacy by 50%, advancing to preclinical development
"ELEM Biotech's expertise in primary cell gene editing was crucial for our CAR-T optimization program. Their systematic approach and technical excellence delivered results beyond our expectations."
— Multinational Pharmaceutical R&D Center